Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
Authors:
- Antonio González-MartínAGAntonio González-Martín
- Hyun Cheol ChungHCHyun Cheol Chung
- Esma Saada-BouzidESEsma Saada-Bouzid
- Eduardo YanezEYEduardo Yanez
- Helene SenellartHSHelene Senellart
- Philippe A. CassierPCPhilippe A. Cassier
- Bradley R. CorrBCBradley R. Corr
- Eugenia GirdaEGEugenia Girda
- Corina DutcusCDCorina Dutcus
- Chinyere E. OkparaCOChinyere E. Okpara
- Razi GhoriRGRazi Ghori
Open Access
- 7 May 2024
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 186, 182-190
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)Annals of Oncology, 2022
- Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal CancerGynecologic Oncology, 2021
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian CancerJAMA Oncology, 2021
- Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trialGynecologic Oncology, 2020
- LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumoursAnnals of Oncology, 2020
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology, 2019
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialThe Lancet Oncology, 2019
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028Gynecologic Oncology, 2019
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialThe Lancet Oncology, 2015